# Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

> **NCT07673016** · — · RECRUITING · sponsor: **Convergent Genomics, Inc.** · enrollment: 2500 (estimated)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma (UC)
- Hematuria
- Upper Tract Urothelial Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07673016
- **Lead sponsor:** Convergent Genomics, Inc.
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-15
- **Primary completion:** 2034-12
- **Final completion:** 2034-12
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*